Tacalcitol: Difference between revisions
Jump to navigation
Jump to search
Marked this version for translation |
|||
| Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
<translate> | <translate> | ||
<!--T:1--> | |||
{{Short description|Chemical compound}} | {{Short description|Chemical compound}} | ||
{{Drugbox | {{Drugbox | ||
| Line 9: | Line 10: | ||
| image = Tacalcitol.svg | | image = Tacalcitol.svg | ||
<!--T:2--> | |||
<!--Clinical data--> | <!--Clinical data--> | ||
| tradename = | | tradename = | ||
| Line 22: | Line 24: | ||
| routes_of_administration = Topical | | routes_of_administration = Topical | ||
<!--T:3--> | |||
<!--Pharmacokinetic data--> | <!--Pharmacokinetic data--> | ||
| bioavailability = | | bioavailability = | ||
| Line 29: | Line 32: | ||
| excretion = | | excretion = | ||
<!--T:4--> | |||
<!--Identifiers--> | <!--Identifiers--> | ||
| CAS_number_Ref = {{cascite|correct|??}} | | CAS_number_Ref = {{cascite|correct|??}} | ||
| Line 46: | Line 50: | ||
| ChemSpiderID = 4446823 | | ChemSpiderID = 4446823 | ||
<!--T:5--> | |||
<!--Chemical data--> | <!--Chemical data--> | ||
| C=27 | H=44 | O=3 | | C=27 | H=44 | O=3 | ||
| Line 56: | Line 61: | ||
}} | }} | ||
<!--T:6--> | |||
'''Tacalcitol''' (1,24-dihydroxyvitamin D<sub>3</sub>) is a synthetic [[vitamin D3|vitamin D<sub>3</sub>]] analog. Tacalcitol is marketed under several names, including '''Curatoderm''' and '''Bonalfa'''. | '''Tacalcitol''' (1,24-dihydroxyvitamin D<sub>3</sub>) is a synthetic [[vitamin D3|vitamin D<sub>3</sub>]] analog. Tacalcitol is marketed under several names, including '''Curatoderm''' and '''Bonalfa'''. | ||
<!--T:7--> | |||
It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. | ||
<!--T:8--> | |||
==Mechanism== | ==Mechanism== | ||
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with [[vitamin D receptor]]s on [[keratinocytes]]. | Tacalcitol reduces excessive cell turnover in the epidermis by interacting with [[vitamin D receptor]]s on [[keratinocytes]]. | ||
<!--T:9--> | |||
==Uses== | ==Uses== | ||
It is usually prescribed by a general practitioner or dermatologist for the treatment of [[psoriasis]], chronic [[chapped lips]] and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion. | It is usually prescribed by a general practitioner or dermatologist for the treatment of [[psoriasis]], chronic [[chapped lips]] and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion. | ||
<!--T:10--> | |||
It has also been used for [[vitiligo]] and [[Hailey-Hailey disease]]. | It has also been used for [[vitiligo]] and [[Hailey-Hailey disease]]. | ||
<!--T:11--> | |||
{{Antipsoriatics}} | {{Antipsoriatics}} | ||
{{Vitamin D receptor modulators}} | {{Vitamin D receptor modulators}} | ||
<!--T:12--> | |||
{{二次利用|date=11 February 2024}} | {{二次利用|date=11 February 2024}} | ||
[[Category:Secosteroids]] | [[Category:Secosteroids]] | ||
Latest revision as of 23:02, 12 April 2024
 | |
| Clinical data | |
|---|---|
| Other names | (1α,24R)-1,24-Dihydroxyvitamin D3 |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H44O3 |
| Molar mass | 416.646 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic vitamin D3 analog. Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
It is on the World Health Organization's List of Essential Medicines.
Mechanism
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with vitamin D receptors on keratinocytes.
Uses
It is usually prescribed by a general practitioner or dermatologist for the treatment of psoriasis, chronic chapped lips and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover. It is available as an ointment or lotion.
It has also been used for vitiligo and Hailey-Hailey disease.
 | この記事は、クリエイティブ・コモンズ・表示・継承ライセンス3.0のもとで公表されたウィキペディアの項目Tacalcitol(11 February 2024編集記事参照)を素材として二次利用しています。 Item:Q22024  |